The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
BACKGROUND
Minimal residual disease (MRD) assessment predicts survival for patients with newly diagnosed acute lymphoblastic leukemia (ALL). Its significance in relapsed/refractory ALL is less clear.
METHODS
This study identified 78 patients with relapsed/refractory B‐cell ALL who achieved a morphologic response with inotuzumab ozogamicin (n = 41), blinatumomab (n = 11), or mini‐hyperfractionated...
BACKGROUND
The role of day 14 (D14) bone marrow (BM) assessment in detecting increased blasts in patients undergoing induction for acute lymphoblastic leukemia (ALL) is not well defined.
METHODS
This study evaluated 389 adolescent and adult patients with previously untreated Philadelphia chromosome–negative ALL who received frontline induction chemotherapy and for whom a D14 BM assessment was performed...
BACKGROUND
The clinical efficacy of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (HCVAD) plus ponatinib has not been compared with that of HCVAD plus dasatinib in patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph+ ALL) in a randomized clinical trial.
METHODS
The authors analyzed 110 patients with newly diagnosed Ph+ ALL who were enrolled...
BACKGROUND
Various trials have reported improved outcomes for adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) who received treatment with pediatric‐based regimens. Those reports prompted the current investigation of the pediatric augmented Berlin‐Frankfurt‐Münster (ABFM) regimen in AYA patients. The results were compared with those from a similar population that received...
BACKGROUND:CXC chemokine receptor 4 (CXCR4) is activated by phosphorylation (pCXCR4) and is essential for the migration of hematopoietic precursors to bone marrow. CXCR4 overexpression predicts a poor prognosis in patients with acute myeloid leukemia. Data regarding the prognostic impact of CXCR4 in patients with B‐acute lymphoblastic leukemia (B‐ALL) are sparse and limited to the pediatric population...
BACKGROUND:Philadelphia chromosome (Ph)‐positive B‐lymphoblastic leukemia exhibits immunophenotypic, karyotypic, and molecular genetic heterogeneity. The prognostic significance of these parameters was assessed in the context of intensive tyrosine kinase inhibitor (TKI)‐based chemotherapy.
METHODS:The authors studied 65 adult patients with Ph‐positive acute lymphoblastic leukemia (ALL) who received...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.